Radionuclide molecular imaging using Affibody molecules.

Area of Science:

• Oncology
• Molecular Imaging
• Biotechnology

Background:

• Current cancer therapies rely on molecular targets, but only a subset of patients have suitable tumors.
• Radionuclide imaging can help stratify patients for targeted cancer treatment.

Purpose of the Study:

• To evaluate Affibody molecules as a tool for molecular imaging in cancer diagnostics and patient stratification.
• To highlight the potential of Affibody molecules for developing novel targeted cancer therapies.

Main Methods:

• Affibody molecules were engineered for high-affinity recognition of protein targets.
• Site-specific labeling techniques were employed for creating uniform conjugates.
• Pre-clinical and pilot clinical studies utilized various radionuclide labels for SPECT and PET imaging.

Main Results:

• Affibody molecules demonstrated excellent targeting capabilities in pre-clinical models.
• Small size facilitated rapid tumor penetration and clearance from healthy tissues.
• High-contrast in vivo imaging was achieved within hours post-injection.

Conclusions:

• Affibody molecules show significant promise for in vivo molecular imaging of cancer.
• Their characteristics support their use in patient stratification for targeted therapies.
• Further clinical validation is warranted to confirm their therapeutic and diagnostic potential.